Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Tipiracil · Lonsurf

Small molecule · Inhibitor of thymidine phosphorylase · developed by Taiho Pharmaceutical Co.

Approved FDA
1 Registered trials

What is Tipiracil?

Tipiracil is a thymidine phosphorylase inhibitor that is combined with trifluridine in a fixed-ratio oral formulation. By blocking thymidine phosphorylase, it slows the breakdown of trifluridine, increasing its exposure, and it is studied in metastatic colorectal cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Lonsurf
Drug type
Small molecule
Targets
thymidine phosphorylase
Mechanism
Inhibitor of thymidine phosphorylase
Pathways
DNA synthesis, trifluridine metabolism
Therapy area
Oncology
Developer
Taiho Pharmaceutical Co., Ltd.
In trials of
KPTI
FDA status
Approved as Lonsurf, NDA207981 · FDA label
UNII
NGO10K751P

✅ FDA-approved uses

From the indications section of the FDA label (version of Nov 5, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04854434 Phase 2 Metastatic Colorectal Cancer Terminated KPTI

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metastatic Colorectal Cancer

Sources

Updated Oct 18, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.